Tradestie Institutional Equity Comparison Engine

GRML vs MDCX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MDCX Overall Edge

MDCX Captures Institutional Edge (1โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicus Pharma Ltd. Common Stock (MDCX) driven by superior Growth & Margin while GRML counters with relative strength in Momentum & Technical. Fundamentally, GRML trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus MDCX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, GRML sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MDCX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
GRML N/M vs MDCX N/M Fwd P/E
Growth & Margin Winner MDCX
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner GRML
1Y +650.0% vs -25.7% ยท 52W Pos 19% vs 35%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
GRML US Equity
GRML
Institutional Equity
$3.51
-2.77% 1D
Market Cap N/A
1M Return -41.5%
1Y Return +650.0%
Forward P/E N/M
Unified AI Score
56.8 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0
MDCX NASDAQ
Medicus Pharma Ltd. Common Stock
Pharmaceutical Preparations
$1.68
-13.85% 1D
Market Cap $3.6M
1M Return -48.31%
1Y Return -25.66%
Forward P/E N/M
Unified AI Score
61.9 / 100 BUY
Tech 83.0 Fund 60.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: GRML +650.0% MDCX -25.66% Spread: +414.0 pp (GRML Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
GRML TTM Op. Margin: N/A MDCX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRML vs MDCX. Trailing 12-month operating profitability (GRML N/A vs MDCX 0.0%) and valuation multiples (GRML N/M vs MDCX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: GRML (1) vs MDCX (7)
Institutional Metric GRML MDCX Criterion Row Winner
Market Capitalization Scale N/A $3.6M Larger Scale MDCX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth MDCX
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin MDCX
Net Profit Margin Profitability N/A 0.0% Higher Margin MDCX
Return on Equity (ROE) Capital Efficiency N/A -7446.1% Higher ROE MDCX
52-Week Range Position Momentum 19% ($0โ€“$18) 35% ($0โ€“$5) Stronger Trend MDCX
Beta / 30D Volatility Risk Regime -5.32ฮฒ ยท 95% Vol -1.42ฮฒ ยท 108% Vol Lower Realized Risk GRML
Unified Institutional Score Composite Signal 56.8 / 100 (HOLD) 61.9 / 100 (BUY) Higher Composite MDCX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full GRML vs MDCX Buy Guide
GRML UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GRML Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MDCX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MDCX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither GRML nor MDCX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.